Efficacy and safety of 15(R/S)-methyl-lipoxin A4 in topical treatment of infantile eczema

British Journal of Dermatology

Volumn 168, Issue 1, 2013, Pages 172-178

  Wu, Sheng Hua ^a   Chen, X Q ^a   Liu, B ^b   Wu, H J ^b   Dong, L ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOXIN A; MOMETASONE FUROATE; PLACEBO;

ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INJURY SEVERITY; LABORATORY; MAJOR CLINICAL STUDY; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; SCORING SYSTEM;

ADMINISTRATION, CUTANEOUS; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; LIPOXINS; MALE; OINTMENTS; PREGNADIENEDIOLS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84872841510     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11177.x     Document Type: Article

References (28)

1. Kang K, Polster AM, Nedorost ST, et al. Atopic dermatitis. In: Dermatology (, Bolognia JL, Jorizzo JL, Rapini RP, eds), 2nd edn. New York: Elsevier Ltd, 2008; 181-94.
2. O'Meara SJ, Rodgers K, Godson C,. Lipoxins: update and impact of endogenous pro-resolution lipid mediators. Rev Physiol Biochem Pharmacol 2008; 160: 47-69.
3. 4 stable analog displays a unique topical anti-inflammatory profile. J Immunol 2002; 169: 7063-70.
4. 4 stable analogues. J Clin Invest 1998; 101: 819-26.
5. Bannenberg G, Moussignac RL, Gronert K, et al. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol 2004; 143: 43-52.
6. 4 and heme-oxygenase in counter-regulating inflammation during corneal wound healing. FASEB J 2007; 21: 2257-66.
7. 4 in endotoxin-induced uveitis. Mol Pharmacol 2008; 74: 154-61.
8. 4 on dermal inflammation and hyperplasia induced by mezerein. Exp Dermatol 2010; 19: e286-8.
9. 4, a potential anti-inflammatory drug targeting the skin. J Dermatol Sci 2011; 62: 64-71.
10. 4 on airway responses in asthmatic subjects. Am Rev Respir Dis 1992; 145: 1281-4.
11. 4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995; 34: 14609-15.
12. 4 on mesangioproliferative nephritis in rats. Prostaglandins Leukot Essent Fatty Acids 2007; 76: 173-80.
13. Berth-Jones J,. Topical therapy. In: Rook's Textbook of Dermatology (, Burns T, Breathnach S, Cox N, Griffiths C, eds), 8th edn. Oxford: Wiley-Blackwell, 2010; 73.7-8.
14. 4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor. Am J Respir Cell Mol Biol 2006; 34: 65-72.
15. Gandy JJ, Snyman JR, van Rensburg CEJ,. Randomized, parallel-group, double-blind, controlled study to evaluate the efficacy and safety of carbohydrate-derived fulvic acid in topical treatment of eczema. Clin Cosm Invest Dermatol 2011; 4: 145-8.
16. Barbier N, Paul C, Luger T, Allen R,. Validation of the eczema area and severity index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus emulsion 1% randomized controlled clinical trials programme. Br J Dermatol 2004; 150: 96-102.
17. Lewis-Jones MS, Finlay AY, Dykes PJ,. The infants' dermatitis quality of life index. Br J Dermatol 2001; 144: 104-10.
18. Friedmann PS, Ardern-Jones MR, Holden CA,. Atopic dermatitis. In: Rook's Textbook of Dermatology (, Burns T, Breathnach S, Cox N, Griffiths C, eds), 8th edn. Oxford: Wiley-Blackwell, 2010; 24.10-18.
19. Estrada-Reyes E, Garcia-Hernandez G, Martinez-Gimeno A, Nava-Ocampo AA,. Effect of extensively hydrolyzed milk formula on growth and resistance to bronchitis and atopic dermatitis in infants and toddlers. J Investig Allergol Clin Immunol 2006; 16: 183-7.
20. Vandenplas Y, Brueton M, Dupont C,. Guidelines for the diagnosis and management of cow's milk protein allergy in infants. Arch Dis Child 2007; 92: 902-8.
21. 4 analogs. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 245-50.
22. 4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med 1997; 185: 1693-704.
23. 4 inhibits TNF-α-induced production of interleukins and proliferation of rat mesangial cells. Kidney Int 2005; 68: 35-46.
24. 4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells. Kidney Int 2006; 69: 248-56.
25. 4 of production of interleukins in endothelial cells by lipopolysaccharide. Inflam Res 2008; 57: 430-7.
26. Aliberti J, Hieny S, Sousa CR, et al. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nature Immunol 2002; 3: 76-82.
27. 4. Nat Med 2002; 8: 1018-23.
28. 1 receptor antagonism. FASEB J 2007; 21: 3877-84.